HMRC's VAT Demands on Free Cancer Drugs Expose a Policy Contradiction

Earlier this year, Bayer suspended new patient enrolments in its UK compassionate use scheme. The medicines involved were not in short supply, and the patients who needed them remained eligible. What changed was a ruling from HM Revenue and Customs, which decided that giving away a life-saving drug free of charge counted as a taxable transaction.

The mechanism behind this is called a "deemed supply". It exists, in principle, to stop companies reclaiming input VAT on goods they later give away without charge. Applied to pharmaceutical compassionate use schemes, where companies supply unlicensed or unfunded medicines to patients with life-threatening conditions, the rule produces a result that is hard to justify on its own terms: a tax bill for an act of charity.

HMRC has since paused enforcement of VAT on free medicines provided after clinical trials, pending a review prompted by complaints from the sector. That is a sensible step, but it does not undo what has already happened. Bayer's withdrawal from new enrolments will not be reversed by a Treasury statement, and other companies will have drawn their own conclusions about how predictable the UK tax environment really is.

The episode sits awkwardly alongside the government's stated ambitions for the sector. The Life Sciences Sector Plan, published last year, sets out a goal of doubling spending on innovative medicines as a share of GDP and making the UK the world's third largest life sciences economy by 2035. Changes to NICE's evaluation methods took effect on 31 March 2026, intended to let through treatments that offer real clinical benefit even where the cost case alone might previously have failed. A pharmaceutical partnership between the UK and the US was announced earlier this year too. On paper, the direction of travel looks deliberate.

In practice, the picture is messier. Since the start of the year, pharmaceutical companies have withdrawn or frozen close to £2.6 billion in planned UK investment. The reasons are not limited to VAT, but the affair has added a concrete grievance to a longer-running set of complaints from an industry that contributes more than £17 billion a year to the economy. England's position for access to new medicines among European countries has fallen from first to ninth in under a decade. Five years after a medicine receives marketing authorisation, UK uptake still averages only 62 per cent of the level seen in comparable countries.

None of this is solely HMRC's doing. Slow commissioning decisions, local NHS budget pressure and the pace of NICE assessments all play a part. But the VAT dispute is different in kind from these slower, structural problems, because it did not need to happen. It was not a funding shortfall or a difficult clinical trade-off. It was a tax authority applying a rule designed for one purpose to a situation it plainly was not written for, and doing so without apparent reference to the government's own priorities elsewhere.

That is the part of the story worth dwelling on. A government can publish sector plans, reform NICE thresholds and sign international partnerships, and still find that a separate arm of the state has been quietly working against all of it. Nobody inside HMRC set out to discourage drug donations to dying patients. The outcome happened anyway, and it took a company actually withdrawing from a patient programme before anyone outside the tax authority noticed.

The review HMRC has launched will settle the immediate question of whether VAT applies to these donated medicines. The harder question, less likely to be resolved by any single review, is whether government has the means to catch this kind of contradiction before a pharmaceutical company has to make the decision Bayer made.